Tesamorelin: What It Is and How It's Used in the Philippines
Tesamorelin reference for Filipino peptide users. GHRH analog for visceral fat reduction. FDA-approved for HIV lipodystrophy. PH protocols and considerations.
Tesamorelin: What It Is and How It's Used in the Philippines
Quick read: Tesamorelin is a GHRH analog FDA-approved for reducing visceral abdominal fat in HIV patients with lipodystrophy. Dosed at 1-2mg daily before bed, it targets stubborn belly fat by elevating GH. In PH, it's used by the BGC/Makati corporate demographic (35-55) with central adiposity and by users stacking it with GLP-1 agonists for aggressive visceral fat loss.
What it is
Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH) with a 44-amino-acid sequence. It signals the pituitary to release GH, which in turn drives lipolysis (fat breakdown), particularly in visceral adipose tissue.
The unique feature of tesamorelin is its targeted effect on visceral fat (the fat around organs, not subcutaneous fat). This makes it clinically valuable for HIV lipodystrophy, where patients accumulate excess visceral fat despite normal or low overall body fat.
Half-life is roughly 26 minutes. The GH pulse peaks within 30-60 minutes and returns to baseline within 2-3 hours, similar to CJC-1295 (no DAC).
Tesamorelin is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy. It's the only GHRH analog with FDA approval for a specific indication, which gives it more clinical backing than other research peptides.
In the PH peptide community, tesamorelin is used off-label for visceral fat reduction in non-HIV users. It's popular among people with central adiposity (belly fat) who have tried diet and training without success.
What it's used for
Primary use: Visceral fat reduction. Tesamorelin targets belly fat specifically. Users run it for 3-6 months to reduce waist circumference and improve metabolic health.
Secondary use: Body recomposition. Elevated GH supports muscle retention and fat oxidation, making tesamorelin useful during caloric deficits.
Tertiary use: Stacking with GLP-1 agonists. Some users stack tesamorelin with retatrutide or semaglutide for dual-mechanism fat loss (GLP-1 for total weight loss, tesamorelin for visceral fat targeting).
Realistic expectations: Users running tesamorelin for 12-24 weeks typically see 1-3cm reduction in waist circumference. The effect is gradual and targets visceral fat more than subcutaneous fat.
Typical protocols
Standard protocol:
- Dose: 1-2mg subcutaneous daily
- Timing: Before bed, on an empty stomach
- Duration: 12-24 weeks
Conservative protocol (first-time users):
- Dose: 1mg daily
- Duration: 12 weeks, then reassess based on waist circumference and bloodwork
Aggressive protocol (advanced users):
- Dose: 2mg daily
- Duration: 24 weeks
Pin location: Subcutaneous, typically abdomen.
Reconstitution: Tesamorelin typically comes as 2mg lyophilized powder. Common setup: 2mg + 2mL BAC water = 1mg/mL. For 2mg dose, use 2mL (entire vial).
Timing: Before bed to align with natural nocturnal GH pulse. Empty stomach (carbs blunt GH release).
What users typically report
Week 1-4: Most users dont notice dramatic changes. Slight improvement in sleep quality. Some users report mild increase in hunger.
Week 5-12: Waist circumference starts to decrease. Belly feels firmer, less bloated. Visceral fat reduction becomes noticeable. Some users report improved insulin sensitivity (fasting glucose drops).
Week 13-24: Continued visceral fat loss. The effect plateaus around week 16-20 for most users.
Variance: Response depends on baseline visceral fat levels. Users with significant central adiposity (waist circumference >100cm for men, >90cm for women) tend to see more dramatic results.
Common side effects
Joint pain or stiffness (10-20%): Related to elevated GH and IGF-1. Usually mild and resolves after stopping or reducing dose.
Edema / water retention (10-15%): Mild bloating or puffiness, especially in hands and feet.
Elevated IGF-1 (expected effect): Tesamorelin raises IGF-1. Excessively high levels (>500 ng/mL) long-term may carry health risks.
Injection site reactions (10%): Redness, swelling, or itching.
Headache (5-10%): Occasionally reported.
Increased hunger (5-10%): Some users feel hungrier due to elevated GH and ghrelin signaling.
Serious side effects: Potential for worsening glucose tolerance or insulin resistance, especially in people with prediabetes or metabolic syndrome. Regular glucose monitoring is recommended.
Side effect management
Joint pain: Reduce dose to 1mg. Ensure adequate hydration. If persistent, stop.
Edema: Reduce sodium intake. Increase water consumption. If severe, reduce dose.
Elevated IGF-1: Check IGF-1 at week 6 and week 12. If >500 ng/mL, reduce dose or stop.
Injection site reactions: Rotate sites. Use fresh needles.
Headache: Stay hydrated. If persistent, reduce dose.
Increased hunger: Pin before bed so hunger happens during sleep.
Who this compound is for
Tesamorelin is for people with stubborn visceral fat who have plateaued on diet and training. Ideal users:
- Ages 35+ with central adiposity (belly fat, high waist circumference)
- Metabolic syndrome or prediabetes (elevated fasting glucose, insulin resistance)
- Users stacking with GLP-1 agonists for compound visceral fat loss
It's especially relevant in the PH demographic of desk workers (BGC/Makati corporate, 40-60) with years of sedentary work and central fat accumulation.
Who this compound is NOT for
People with healthy visceral fat levels: Limited benefit.
Active cancer: GH elevation could promote tumor growth.
Poorly controlled diabetes: Tesamorelin can worsen glucose tolerance.
Pregnancy/breastfeeding: No safety data.
People unwilling to check bloodwork: IGF-1 and glucose should be monitored.
PH-specific considerations
BGC corporate demographic with central adiposity: The "desk job belly" is common in Manila's office culture. Tesamorelin is popular among this demographic for targeted fat loss.
Stacked with GLP-1 agonists: Some PH users run tesamorelin + retatrutide for dual-mechanism fat loss. Protocol: 1-2mg tesamorelin daily + 4-6mg retatrutide weekly.
Cost: Tesamorelin is more expensive than CJC-1295 or BPC-157. Total cycle cost for 12 weeks is typically 15,000-25,000 PHP.
PH labs offer waist circumference tracking: Monitor waist circumference bi-weekly to track progress.
Common stacks
Tesamorelin + Retatrutide: For aggressive fat loss. Retatrutide drives total weight loss, tesamorelin targets visceral fat.
Tesamorelin + CJC + Ipamorelin: For comprehensive GH support (pulsatile GH from CJC + Ipa, visceral fat targeting from tesamorelin).
Tesamorelin + MOTS-c: For metabolic support and insulin sensitivity alongside fat loss.
Things to watch
Bloodwork:
- Baseline: IGF-1, fasting glucose, HbA1c
- Week 6: IGF-1, fasting glucose
- Week 12: IGF-1, fasting glucose, HbA1c
Subjective metrics:
- Waist circumference (bi-weekly)
- Fasting glucose (weekly with home monitor)
PH labs offer IGF-1 for 1500-2500 PHP.
Coming off / cycling
Stop cold after 12-24 weeks. Cycle off for 8-12 weeks.
Related compounds
- Retatrutide — Often stacked with tesamorelin for compound fat loss
- CJC + Ipamorelin — Pulsatile GH stack, can be combined with tesamorelin
- MOTS-c — Metabolic support, stacks well with tesamorelin
Sources
- Falutz 2010 — Tesamorelin for HIV lipodystrophy, visceral fat reduction
- Stanley 2012 — Tesamorelin effects on abdominal fat and cardiovascular risk
Last updated: 2026-05-20. This page is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.